+ FOXP3 + regulatory T cells (Tregs) is a promising strategy to limit organ rejection and graft-vs-host disease. Ongoing clinical applications have yet to consider how human Tregs could be modified to direct their migration to specific inflammation sites and/or tissues for more targeted immunosuppression. We show here that stable, homing-receptor-tailored human Tregs can be generated from thymic Tregs isolated from pediatric thymus or adult blood. To direct migration to that failed to sequentially migrate from the allograft to draining LNs were not activated and could not prevent infiltration of effector T cells into the graft or draining LNs. 
| INTRODUC TI ON
The use of CD4 + FOXP3 + regulatory T cells (Tregs) as a cell therapy to limit transplant rejection or treat autoimmunity is under intense investigation. 1 Multiple groups have developed good manufacturing practices (GMP)-compatible protocols to isolate and expand polyclonal or antigen-specific Tregs, finding that Treg therapy is safe and possibly effective in a variety of transplant and/or autoimmunerelated conditions.
1,2
In parallel to clinical trials, research into Treg therapy mechanisms revealed that their migratory properties are key for their therapeutic effect. Therapeutic Tregs not only need to migrate to lymph nodes (LNs), but they must also traffic to sites of inflammation for effective protection. [2] [3] [4] [5] [6] For example, in an islet transplant model, Tregs Culture conditions for Figures 1-4 , except 2E-G that failed to sequentially migrate from the allograft to draining LNs were not activated and could not prevent infiltration of effector T cells into the graft or draining LNs. 5 An additional consideration is that Tregs also subspecialize to suppress particular types of immune responses. Under the influence of cytokines and metabolites, their phenotype and function is modified to enable regulation of specific immune responses. 7 Specifically, co-expression of T-BET, IRF4, or STAT3 together with FOXP3 is essential for successful regulation of Th (T helper)1-, Th2-, or Th17-responses, respectively. [8] [9] [10] [11] The concept of tailoring therapeutic human Tregs to generate cells that are programmed to suppress specific types of immune responses, and/or traffic to specific locations in vivo, is gaining increasing interest. 2, 12 Here we comprehensively evaluated whether human CD4 + FOXP3 + Tregs can be modified to target their migration towards sites of Th1-inflammation or specific tissues, such as inflamed intestine, and/or to have enhanced suppressive functions that would be relevant for effective control of graft rejection.
| ME THODS

| Study approval
Human and animal research was approved by the University of British Columbia (UBC) Research Ethics Board (H11-03193, H17-01490 and H09-02401) and the UBC Animal Care Committee (A14-0110), respectively.
| Cell isolation
Healthy thymus tissue was dissociated as described 13 
| Cell expansion
Tregs and Tconv were expanded as described. 13 Briefly, cells were stimulated with irradiated (75 Gy) L cells 14 preloaded with α−CD3 mAb (100 ng/mL; UBC AbLab, Vancouver, BC, Canada) at a 1:1 ratio in OpTmizer T-Cell Expansion Media with 1% GlutaMAX (Glu), 1% penicillin/streptomycin (P/S) (all Thermo Fisher Scientific, US) and rapamycin (100 ng/mL) and incubated at 37°C and 5% CO 2 .
Cells were restimulated on day 7 with L cells (without rapamycin) and cultured until day 13. For long-term culture, cells were restimulated on day 7 and 14 with ImmunoCult CD3/CD28/CD2 T cell activators without rapamycin. Recombinant human (rh) IL-2 (Tregs: 1000 IU/mL, Tconv: 100 IU/mL) was added throughout the culture.
rhIL-12 (10 ng/mL), rh-interferon (IFN)-γ (10 ng/mL), rhIL-1β (10 ng/ mL), rhIL-6 (10 ng/mL), rhIL-23 (10 ng/mL), rh-tumor necrosis factor (TNF)-α (20 ng/mL) or retinoic acid (RA, 20 nmol/L) were added as indicated. Media/additives were refreshed every 2-3 days. 
| In vitro suppression
| In vitro migration
Ninety-six-well migration plates (5 μm) containing 10 5 Tregs in chemotaxis media (RPMI, 1% Glu, 1% P/S, 0.1% BSA [bovine pre-incubated with/without anti-β7-integrin or anti-α4β7-integrin mAbs (5 μg/mL) at 37°C for 15 minutes and 1. 
| In vitro adhesion
| Supplemental methods
Detailed methods are available online (supplemental methods) for Flow Cytometry, RNA-sequencing, virus production, T cell transduction, mRNA quantification, and Treg-specific demethylation region (TSDR) analysis.
| Accession number for RNA-sequencing data in GEO
GSE112923.
| Statistical analysis
Statistical tests were performed as indicated using GraphpadPrism 7 software. P values: *P < .05, **P < .01, ***P < .001, and ****P < .0001.
| RE SULTS
| Induction of human CXCR3 + Th1-Tregs
To suppress Th1-mediated inflammation, Tregs must express CXCR3 and T-BET to migrate towards CXCL9, -10, and -11 and colocalize with Th1 cells. 8, 10, 17 In blood, ≈30% of memory Tregs express CXCR3, 18 but isolating and expanding this small fraction, potentially contaminated with Th1-effector cells, is impractical for clinical applications. Expression of CXCR3 and T-BET can be induced by exposing Tregs to Th1-polarizing cytokines, ie, IFN-γ and We next performed RNA-sequencing to investigate whether induced Th1-Tregs had a Th1-polarized transcriptome, similar to ex-vivo Th1-Tregs. 25 A total of 40 and 216 genes were differentially expressed in Th1→0 and Th1→Th1 Tregs compared to neutral Tregs, respectively (P < .05 and log 2 fold-change >1 or <−1, Figure 3A ,B). Genes previously found to be increased in ex-vivo Figure 1B) . Colored dots represent significantly (adjusted P < .05, log 2 fold-change >1 or <−1) up-or downregulated genes. Selected genes of interest are labeled and genes significant in both Th1→0 and Th1→Th1 are in bold with (*). C,D, Log 2 fold-change of the most significant (adjusted P < .05) up-and downregulated genes for Treg Th1→0 (C) or Treg Th1→Th1 (D) compared to neutral Tregs, ordered by log 2 fold-change. Genes present in both Th1→0 and Th1→Th1 are in bold with (*). N = 3/condition, DESeq2 in R for normalization and computation of differential expression with BenjaminiHochberg correction to adjust P values for multiple testing. CCL, chemokine; CCR/CXCR, chemokine receptor; IFN, interferon; IGFBP, insulin-like growth factor binding protein 3; IL, interleukin; Th, T helper; TNF, tumor necrosis factor; Tregs, regulatory T cells [Color figure can be viewed at wileyonlinelibrary.com] of latency-associated peptide (LAP) or glycoprotein A repetitions predominant (GARP) (Figure 4A,B) . In mice, Th1-Tregs are required to suppress Th1-mediated responses in vivo. 8 cells, as judged by production of IFN-γ and expression of T-BET ( Figure 4E ). We also tested the function of Th1-Tregs in a humanized mouse model of xenoGVHD. Mice that received Th1-Tregs had improved survival compared to PBMC-only mice, but there was no significant difference between the Treg groups ( Figure 4F ).
Since Th1-Tregs do not appear to be specialized to suppress Th1 cells in vitro, their improved function in vivo 8, 10, 17, 32 is likely related to their increased homing capacity to sites of Th1-inflammation.
Indeed, using a transwell chemotaxis assay, all Tregs migrated towards CCL22, the ligand for CCR4 ( Figure S1E ), but only Th1-Tregs migrated towards CXCL10, a ligand for CXCR3 that is prevalent at sites of Th1-inflammation 34 ( Figure 4G ). Migration towards CXCL10
was CXCR3 dependent because it was specifically blocked by neutralizing α-CXCR3 but not by control α-CCR7 mAbs. 
| Generation of human Tregs with a guthoming phenotype
In addition to inflammation-directed migration, it would be beneficial to direct Treg migration towards specific tissues. Because the intestine is one of the major target tissues in GVHD and highly susceptible to rejection after intestinal transplantation, 35 . ANOVA, analysis of variance; CCR/CXCR, chemokine receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CCL/ CXCL, chemokine; GARP, glycoprotein A repetitions predominant; IFN-γ, interferon-γ; IL, interleukin; LAP, latency-associated peptide; mAbs, monoclonal antibodies; MFI, mean fluorescence intensity; n.s., not significant; SD, standard deviation; Tconv, conventional T cells; xenoGVHD, xenogeneic graft-vs-host disease. **P < .01, ***P < .001, ****P < .0001 [Color figure can be viewed at wileyonlinelibrary.com] ITGA4, and DHRS3, 51, 52 were highly upregulated ( Figure 7A ). RA treatment downregulated CCR7 and SELL (CD62L) (confirming data in Figure 5D and consistent with gut-homing), IL6R 45 , and SEMA4A, which is of unknown significance. Of specific interest was the highly significant downregulation of FUT7 and CNTNAP1. FUT7, a fucosyltransferase important for fucosylation of E-and P-selectin ligands, 53 is known to be downregulated by RA. 54, 55 CNTNAP1 is associated with a Th2-phenotype in human T cells, 27 but its role in Tregs is unclear ( Figure 7B ). Interestingly, as in Th1-Tregs, expression of METTL7A was highly increased in RA-Tregs. Stable expression of CXCR3, even after removal of Th1-polarizing cytokines, culture in Th17-polarizing cytokines or injection in vivo, and efficient migration to CXCL10 in vitro suggests that these in vitro-tailored Th1-Tregs would be well adapted to localize to Th1-inflammatory sites.
| RA-
| D ISCUSS I ON
We are, to the best of our knowledge, the first to show that ex- Importantly, the ability to tailor Treg homing is not restricted to sites of inflammation; tissue-targeted migration can also be induced. Specifically, RA significantly upregulated gut-homing markers α4β7-integrin and CCR9 on human ex-vivo Tregs and induced a transcriptional profile consistent with gut-homing. Indeed, FUT7, an enzyme involved in T cell-homing to skin and inflammatory sites, 55 was the most significantly downregulated gene in RA-treated compared to neutral Tregs, suggesting that RA treatment diverts Treg-homing from skin to gut. RA-induced α4β7-integrin expression was remarkably stable during long-term culture in vitro even after removal of RA and was only diminished when cells were exposed to an alternate Th17-environment. Since intestinal inflammation is often characterized by Th17-inflammation, 64 this finding warrants further investigation. Gut-homing receptors were stably expressed on human RA-Tregs circulating in blood even after injection in vivo, confirming data from mouse RA-Tregs. 38 We are the first to show that the RA-induced α4β7-integrin on human RA-Tregs is functional and enables adherence to MAdCAM-1 in vitro and migration to healthy and inflamed Tregs from healthy subjects, Tregs from patients with ulcerative colitis expressed more α4β7-integrin and migrated more efficiently to the inflamed mucosa in DSS-treated NSG mice. 58 In hematopoi- to different tissues such as the skin or the lung.
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